10月27日，基因编辑公司Intellia Therapeutics盘前一度暴跌超60%，消息面上，该公司宣布暂停其针对转甲状腺素蛋白淀粉样伴心肌病（ATTR-CM）和多神经病（ATTR-PN）患者的给药和筛查程序。
受上述消息影响，美股基因编辑概念股盘前集体下挫，Beam Therapeutics跌超10%，Editas Medicine跌超8%，CRISPR Therapeutics跌超5%。
10月27日，基因编辑公司Intellia Therapeutics盘前一度暴跌超60%，消息面上，该公司宣布暂停其针对转甲状腺素蛋白淀粉样伴心肌病（ATTR-CM）和多神经病（ATTR-PN）患者的给药和筛查程序。
受上述消息影响，美股基因编辑概念股盘前集体下挫，Beam Therapeutics跌超10%，Editas Medicine跌超8%，CRISPR Therapeutics跌超5%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.